| Fiscal Year End | Company Status | Exempt Flag |
| March 31 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 5/May/2009 | 11/Nov/2020 | Canada | Ontario | |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Research and Development in the Physical, Engineering and Life Sciences
| News Release October 3, 2014 - Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's ATB-346 targets the global need for safer non-steroidal anti-inflammatory drugs (NSAIDs).
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *ATE | *Antibe Therapeutics Inc. | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *Antibe Therapeutics Inc. | 22/Mar/2013 | 11/Nov/2020 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
